Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genprex Inc (GNPX)

Genprex Inc (GNPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 149,764
  • Shares Outstanding, K 39,937
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,650 K
  • 60-Month Beta -0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.61
Trade GNPX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.28
  • Number of Estimates 1
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.51 +10.26%
on 01/12/21
5.72 -32.34%
on 12/23/20
-0.60 (-13.42%)
since 12/22/20
3-Month
2.84 +36.27%
on 10/28/20
5.72 -32.34%
on 12/23/20
+0.51 (+15.18%)
since 10/22/20
52-Week
1.09 +255.05%
on 01/23/20
7.03 -44.95%
on 02/25/20
+1.98 (+104.76%)
since 01/22/20

Most Recent Stories

More News
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 3.90 (+4.00%)
Genprex to Present at NobleCon17 on January 19

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 3.90 (+4.00%)
Genprex Achieves Major Manufacturing Milestone for REQORSA(TM) Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer

Genprex, Inc. ("Genprex" or the "Company") (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that...

GNPX : 3.90 (+4.00%)
Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants

Genprex, Inc. (Nasdaq: GNPX) ("Genprex" or the "Company"), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the...

GNPX : 3.90 (+4.00%)
Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants

Genprex, Inc. (Nasdaq: GNPX) ("Genprex" or the "Company"), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it...

GNPX : 3.90 (+4.00%)
Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA(TM) Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

--Achievement Highlighted by Important Process Improvements and Significantly Improved Economies of Scale

GNPX : 3.90 (+4.00%)
Genprex (GNPX) Looks Good: Stock Adds 6.5% in Session

Genprex (GNPX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

RGEN : 217.72 (+0.37%)
GNPX : 3.90 (+4.00%)
Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy

--Manufacturing Technology Transfer Marks Major Company Milestone

GNPX : 3.90 (+4.00%)
Genprex to Present at the Benzinga Global Small Cap Conference on December 8

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that...

GNPX : 3.90 (+4.00%)
Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

--Company expects to recruit approximately 10 sites across the United States

GNPX : 3.90 (+4.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 4.11
2nd Resistance Point 4.03
1st Resistance Point 3.89
Last Price 3.90
1st Support Level 3.67
2nd Support Level 3.59
3rd Support Level 3.45

See More

52-Week High 7.03
Fibonacci 61.8% 4.76
Fibonacci 50% 4.06
Last Price 3.90
Fibonacci 38.2% 3.36
52-Week Low 1.09

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar